Cytokinetics to Present at March Investor Conferences
March 05 2018 - 4:00PM
Cytokinetics, Incorporated (Nasdaq:CYTK) announced today that
Robert I. Blum, President and Chief Executive Officer, is scheduled
to present a corporate update at the following investor
conferences:
- Cowen and Company 38th Annual Health
Care Conference on Monday, March 12,
2018 at 2:50 PM EST at the Boston Marriott
Copley Place Hotel in Boston
- 17th Annual Needham Healthcare
Conference on Tuesday, March 27,
2018 at 10:00 AM EST at the Westin Grand Central
Hotel in New York
Interested parties may access the live webcast
of this presentation by visiting the Investors & Media section
of the Cytokinetics website at www.cytokinetics.com. The webcast
replay of the presentation will be archived on the Presentations
page within the Investors & Media section of Cytokinetics'
website for 90 days following the conclusion of the event.
About Cytokinetics
Cytokinetics is a late-stage biopharmaceutical
company focused on discovering, developing and commercializing
first-in-class muscle activators as potential treatments for
debilitating diseases in which muscle performance is compromised
and/or declining. As a leader in muscle biology and the mechanics
of muscle performance, the company is developing small molecule
drug candidates specifically engineered to increase muscle function
and contractility. Cytokinetics is collaborating with Amgen Inc.
(“Amgen”) to develop omecamtiv mecarbil, a novel cardiac muscle
activator. Omecamtiv mecarbil is the subject of GALACTIC-HF, an
international Phase 3 clinical trial in patients with heart
failure. Amgen holds an exclusive worldwide license to develop and
commercialize omecamtiv mecarbil with a sublicense held by Servier
for commercialization in Europe and certain other countries.
Cytokinetics is collaborating with Astellas Pharma Inc.
(“Astellas”) to develop reldesemtiv (CK-2127107), a next-generation
FSTA. Reldesemtiv has been granted orphan drug designation by the
FDA for the potential treatment of SMA. Reldesemtiv is the subject
of three ongoing Phase 2 clinical trials enrolling patients with
spinal muscular atrophy, chronic obstructive pulmonary disease and
ALS. Astellas is also conducting a Phase 1b clinical trial of
reldesemtiv in elderly adults with limited mobility. Astellas holds
an exclusive worldwide license to develop and commercialize
reldesemtiv. Licenses held by Amgen and Astellas are subject to
Cytokinetics' specified co-development and co-commercialization
rights. Cytokinetics continues its 20-year history of innovation
with three new muscle biology directed compounds advancing from
research to development in 2018. For additional information
about Cytokinetics, visit www.cytokinetics.com.
Forward-Looking Statements
This press release contains forward-looking
statements for purposes of the Private Securities Litigation Reform
Act of 1995 (the "Act"). Cytokinetics disclaims any intent or
obligation to update these forward-looking statements, and claims
the protection of the Act's Safe Harbor for forward-looking
statements. Examples of such statements include, but are not
limited to, statements relating to Cytokinetics' and its partners'
research and development activities of Cytokinetics’ product
candidates. Such statements are based on management's current
expectations, but actual results may differ materially due to
various risks and uncertainties, including, but not limited to the
risks related to Cytokinetics' business outlined in Cytokinetics'
filings with the Securities and Exchange Commission.
Forward-looking statements are not guarantees of future
performance, and Cytokinetics' actual results of operations,
financial condition and liquidity, and the development of the
industry in which it operates, may differ materially from the
forward-looking statements contained in this press release. Any
forward-looking statements that Cytokinetics makes in this press
release speak only as of the date of this press release.
Cytokinetics assumes no obligation to update its forward-looking
statements whether as a result of new information, future events or
otherwise, after the date of this press release.
Contact:
Cytokinetics
Diane
Weiser
Vice President, Corporate Communications, Investor Relations(650)
624-3060
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Sep 2023 to Sep 2024